Molecular Targeting Technologies, Inc.

Molecular Targeting Technologies, Inc. (MTTI) is a privately held US-based Biotechnology Company developing novel medical imaging products for the diagnosis of cardiovascular disease and cancer. MTTI is also developing a novel recombinant rabies vaccine for the oral vaccination of wildlife, as well as human anti-rabies monoclonal antibodies for post-exposure prophylaxis of rabies in China. The wildlife rabies vaccine has progressed to final stages of development having demonstrated genetic stability, and safety and efficacy in target animals such as raccoons, skunks and mongoose. The company is in licensing negotiations with a major animal healthcare company. The company has recently acquired rights to a unique fusion protein technology for the development of potent vaccines. This technology will initially be targeted to the development of Anthrax and Botulinum Vaccine.

Contact Details: Tel: (610) 738-7938 Fax: (610) 738-7928 Email: info@mtarget.com WWW: www.mtarget.com/

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 280 times since April 2007, the link to the organisation's website has been followed 63 times

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Molecular Targeting Technologies, Inc.